Skip to main content

Table 2 Multiple linear regression models displaying adjusted estimates for lnFGF19 for outcomes of arteriosclerosis parameters adjusted for the other clinical covariates in each model in patients with T2D

From: Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes

Models

B (95% CI)

β

t

p

R2 for model

baPWV

 Model 0: unadjusted

− 167.6 (− 227.0 to − 108.3)

− 0.37

− 5.57

< 0.001

0.135

 Model 1: age, sex, BMI and duration

− 161.8 (− 218.7 to − 104.9)

− 0.36

− 5.61

< 0.001

0.241

 Model 2: Model 1 + SBP, DBP, hypertension, statins, NAFLD, NFS, UA, TC, TG, HDLC, LDLC, and Lpa

− 98.7 (− 171.5 to − 26.0)

− 0.22

− 2.70

0.008

0.587

 Model 3: Model 2 + ISHOMA-cp, HbA1c and antidiabetic treatments

− 86.8 (− 164.5 to − 9.1)

− 0.20

− 2.23

0.029

0.599

lnAIP

 Model 0: unadjusted

− 0.22 (− 0.32 to − 0.12)

− 0.30

− 4.46

< 0.001

0.091

 Model 1: age, gender, BMI and diabetic duration

− 0.21 (− 0.30 to − 0.11)

− 0.28

− 4.19

< 0.001

0.145

 Model 2: Model 1 + SBP, DBP, hypertension, statins, NAFLD, NFS, UA, TC, LDLC and Lpa

− 0.21 (− 0.35 to − 0.07)

− 0.29

− 3.03

0.003

0.342

 Model 3: Model 2 + ISHOMA-cp, HbA1c and antidiabetic treatments

− 0.21 (− 0.36 to − 0.05)

− 0.28

− 2.66

0.010

0.491